Betanaz

Country of origin: India
Pharm-Group: Antidiabetic agents - sulfonylurea derivatives

Manufacturers: Cadila Pharmaceuticals (India)
International name: Glibenclamide
Synonyms: Antibet, Apo-Glyburide, Betanase, Gen-Glib, Gilemal, Glamid, Glibamid, Glibenclamide, Glibenclamide AVD 5, Glibenclamide Nycomed, Glidanil, Glimidstada 1.75 Shtad, Glimidstad 3.5 Shtad, Glinil, Glucobene, Glucomid, Daonil, Diab-control , Diabetes, Maniglide

Dosage forms: 5 mg tablets
Composition: Active ingredient - Glibenclamide.

Indications for use: Diabetes mellitus type 2 when it is impossible to compensate for hyperglycemia with diet, weight loss, and physical activity.

Contraindications: Hypersensitivity (including to sulfonamide drugs, thiazade diuretics), diabetic precomatose and comatose state, ketoacidosis, extensive burns, surgery and trauma, intestinal obstruction, gastric paresis; conditions accompanied by impaired absorption of food, the development of hypoglycemia (infectious diseases, etc.); hypo- or hyperthyroidism, impaired liver and kidney function, leukopenia, type 1 diabetes mellitus, pregnancy, breastfeeding.

Side effects: From the cardiovascular system and blood (hematopoiesis, hemostasis): rarely - thrombocytopenia, granulocytopenia, erythrocytopenia, pancytopenia, eosinophilia, leukocytopenia, agranulocytosis (very rarely), in some cases - hypoplastic or hemolytic anemia. From the nervous system and sensory organs: headache, dizziness, changes in taste. Metabolic: hypoglycemia, proteinuria, porphyria cutanea tarda. From the gastrointestinal tract: liver dysfunction, cholestasis, dyspepsia. Allergic reactions: skin rashes (erythema, exfoliative dermatitis). Other: fever, arthralgia, polyuria, weight gain, photosensitivity.

Interaction: Systemic antifungals (azole derivatives), fluoroquinolones, tetracyclines, chloramphenicol (inhibits metabolism), H2-blockers, beta-blockers, ACE inhibitors, NSAIDs, MAO inhibitors, clofibrate, bezafibrate, probenecid, paracetamol, ethionamide, anabolic steroids, pentoxifylline, allopurinol, cyclophosphamide, reserpine, sulfonamides, insulin - potentiate hypoglycemia. Barbiturates, phenothiazines, diazoxide, glucocorticoid and thyroid hormones, estrogens, gestagens, glucagon, adrenomimetic drugs, lithium salts, nicotinic acid derivatives and saluretics weaken the hypoglycemic effect.

Overdose: Symptoms: hypoglycemia (feeling of hunger, severe weakness, anxiety, headache, dizziness, sweating, palpitations, muscle tremors, cerebral edema, speech and vision disorders, impaired consciousness and hypoglycemic coma, possible death)

Special instructions: To prevent hypoglycemic conditions, you should strictly observe regular intake. It is mandatory to eat food no later than 1 hour after using the drug. During treatment, dynamic monitoring of serum glucose levels is necessary. Use with caution in elderly patients. When treating with glibenclamide, it is necessary to avoid drinking alcohol, stay in the sun for long periods of time, and limit the consumption of fatty foods. At the beginning of treatment, activities that require increased reaction speed are not recommended. For more detailed information, see the instructions for use.

Literature: Encyclopedia of Medicines 2004